Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
0.5 Ml Dose Of Pcv20, 0.5 Ml Of The Low Dose Vax-31, 0.5 Ml Of The Mid Dose Vax-31, 0.5 Ml Of The High Dose Vax-31, 0.5 Ml Of The High-Pfs Dose Vax-31
Pneumococcal Vaccines
Phase II
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
Dec 02, 2024
―
31 Valent Pneumococcal Conjugate Vaccine, 20 Valent Pneumococcal Conjugate Vaccine
Pneumococcal Vaccines
Phase I/II
Completed
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
Nov 10, 2023
―
0.5 Ml Dose Of 1.1 Mcg Vax-24, 0.5 Ml Dose Of Pcv20, 0.5 Ml Dose Of 2.2 Mcg Vax-24, 0.5 Ml Dose Of 2.2/4.4 Mcg Vax-24
Pneumococcal Vaccines
Phase II
Completed
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
Apr 24, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Vaxcyte, Inc. (PCVX) have in its pipeline
PCVX is currently developing the following drugs: 0.5 Ml Dose Of Pcv20, 0.5 Ml Of The Low Dose Vax-31, 0.5 Ml Of The Mid Dose Vax-31, 0.5 Ml Of The High Dose Vax-31, 0.5 Ml Of The High-Pfs Dose Vax-31, 31 Valent Pneumococcal Conjugate Vaccine, 20 Valent Pneumococcal Conjugate Vaccine, 0.5 Ml Dose Of 1.1 Mcg Vax-24, 0.5 Ml Dose Of Pcv20, 0.5 Ml Dose Of 2.2 Mcg Vax-24, 0.5 Ml Dose Of 2.2/4.4 Mcg Vax-24. These drug candidates are in various stages of clinical development as the company works toward FDA approval.